Studies Including Information on the Stability of Agents in ALZET® Osmotic Pumps
Q3622 Savolainen,M.H., Richie,C.T., Harvey,B.K., Maennistoe,P.T., Maguire-Zeiss,K.A., Myoehaenen,T.T., Myoehaenen,T.T. The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse. NEUROBIOLOGY OF DISEASE 2014; 68(--):1-15. >>> KYP-2047; DMSO; saline; IP; Mice (transgenic); 28 days; Controls received mp w/ vehicle; animal info (Snca tm(A30P) or WT, 12-13 months old); functionality of mp verified by decrease in PREP activity; 50% DMSO used; neurodegenerative (Parkinson's disease; Lewy body dementia); post op. care (buprenorphine); stability verified by (stability experiment one month); pumps primed overnight in 37C saline; KYP-2047 is a enzyme inhibitor (PREP);.
Q3616 Roman,C.W., Lezak,K.R., Hartsock,M.J., Falls,W.A., Braas,K.M., Howard,A.B., Hammack,S.E., May,V., May,V. PAC1 receptor antagonism in the bed nucleus of the stria terminalis (BNST) attenuates the endocrine and behavioral consequences of chronic stress. Psychoneuroendocrinology 2014; 47(--):151-165. >>> Pituitary adenylate cyclase activating polypeptide; Saline; BSA; CSF/CNS; Rat; 2002; 14 days; Animal info (male, adult); behavioral testing (novel object recognition, open field, elevated plus maze); stability verified by (radioimmunoassays; 4% loss per day); cardiovascular; Cannula placement verified via crestyl violet staining and visual inspection; pituitary adenylate cyclase activating polypeptide aka PACP (6-38); delayed delivery; catheters filled with vehicle; pumps primed; PACAP (6-38) is a PAC1 receptor antagonist; stress; y-connector; PACAP (6-38)75uM;.
Q3426 Calcagnoli,F., Meyer,N., de Boer,S.F., Althaus,M., Koolhaas,J.M., Calcagnoli,F. Chronic enhancement of brain oxytocin levels causes enduring anti-aggressive and pro-social explorative behavioral effects in male rats. Hormones and Behavior 2014; 65(--):427-433. >>> Oxytocin, synthetic; antagonist, peptidergic oxytocin; Saline, sterile, pyrogen-free; CSF/CNS; Rat; 1007D; 7 days; Controls received mp w/ vehicle; animal info (male, Groningen, adult); ALZET brain infusion kit 2 used; behavioral testing (resident intruder test); stability verified by (pilot study; 44% destruction of OVT over 10 day period in vivo); peptides; Cannula placement verified via dye injection after sacrifice; Plastics One guide cannula; dental acrylic cement and two stainless steel screws; pumps and catheters incubated in room temperature saline overnight;.
Q3417 Ben Menachem-Zidon,O., Ben Menahem,Y., Ben Hur,T., Yirmiya,R. Intra-Hippocampal Transplantation of Neural Precursor Cells with Transgenic Over-Expression of IL-1 Receptor Antagonist Rescues Memory and Neurogenesis Impairments in an Alzheimer's Disease Model. Neuropsychopharmacology 2014; 39(-2-):401-414. >>> Interleukin-1, receptor antagonist; CSF/CNS; Mice (transgenic); 28 days; Controls received mp w/ vehicle; animal info (WT and Tg2576, 11 months old); pumps replaced every 2 weeks; ALZET brain infusion kit 3 used; neurodegenerative (Alzheimer's disease); behavioral testing (fear conditioning; morris water maze); stability verified by (IL-1-ra remains effective for 2 weeks in pumps); Used three anchoring screws;.
Q3365 Walters,M.J., Ebsworth,K., Berahovich,R.D., Penfold,M.E.T., Liu,S.C., Al Omran,R., Kioi,M., Chernikova,S.B., Tseng,D., Mulkearns-Hubert,E.E., Sinyuk,M., Ransohoff,R.M., Lathia,J.D., Karamchandani,J., Kohrt,H.E.K., Zhang,P., Powers,J.P., Jaen,J.C., Schall,T.J., Merchant,M., Recht,L., Brown,J.M. Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats. British Journal of Cancer 2014; 110(-5-):1179-1188. >>> CCX662; SC; Rat (pregnant); 2004; 2 weeks; 4 weeks;; Controls received mp w/ vehicle; animal info (Sprague Dawley, 115 days old); functionality of mp verified by plasma levels sampled at 9 and 16 days post implantation; pumps replaced every 7 days; cancer (glioblastoma); stability verified by (IC90 value after 16 days); CCX662 is a CXCR7 inhibitor.
Q3340 Grommes,C., Karlo,J.C., Caprariello,A., Blankenship,D., DeChant,A., Landreth,G.E. The PPARgamma agonist pioglitazone crosses the blood-brain barrier and reduces tumor growth in a human xenograft model. Cancer Chemotherapy and Pharmacology 2013; 71(-4-):929-936. >>> Pioglitazone; Dulbecco's modified eagle medium; CSF/CNS; Mice (SCID); 2004; 21 days; Controls received mp w/ vehicle; animal info (Balb/CJHanHsd-Prkdc-SCID, 6 weeks old); ALZET brain infusion kit used; comparison of oral dosing vs mp; cancer (tumors); dose-response (CNS); stability verified by (p.934 - incubation at 37C for 21 days); "Intracerebral treatment with 1 lM pio prolonged survival significantly from 49 to 68 days... This defines the minimal effective dose for oral pio treatment at 240 PPM (20.2 mg/kg) and for intracerebral pio treatment at 1 lM (0.11 ug/kg)." pg 932;.
Q3232 Ke,J.T., Li,M., Xu,S.Q., Zhang,W.J., Jiang,Y.W., Cheng,L.Y., Chen,L., Lou,J.N., Wu,W. Gliquidone decreases urinary protein by promoting tubular reabsorption in diabetic Goto-Kakizaki rats. Journal of Endocrinology 2014; 220(-2-):129-141. >>> Gliquidone; Dimethylformamide; IP; Rat; 7 days; Animal info (male, SPF-grade, Goto-Kakizaki, 8 weeks old, 250-300g); functionality of mp verified by blood drug levels; 99.8% dimethylformamide used; comparison of intragastric administration vs mp (pg.133); stability verified by (plasma serum); diabetes;.
Q3188 Guo,X., Disatnik,M.H., Monbureau,M., Shamloo,M., Mochly-Rosen,D., Qi,X. Inhibition of mitochondrial fragmentation diminishes Huntington's disease-associated neurodegeneration. Journal of Clinical Investigation 2013; 123(-12-):5371-5388. >>> P110-TAT; SC; Mice (transgenic); 8 weeks; Controls received mp w/TAT control peptide; animal info (R6/2 HD model, 5 weeks old); functionality of mp verified by FITC positive signal in neurons pg 5379; pumps replaced every 28 days; neurodegenerative (Huntington's disease); no stress (see pg.5381, 5383); behavioral testing (motor function and behaviors); stability verified by (HPLC with UV detection for 28 days); long-term study; peptides; P110-TAT is a Drp1-selective peptide inhibitor.
Q2667 Geurts,L., Muccioli,G.G., Delzenne,N.M., Cani,P.D. Chronic Endocannabinoid System Stimulation Induces Muscle Macrophage and Lipid Accumulation in Type 2 Diabetic Mice Independently of Metabolic Endotoxaemia. PLoS One 2013; 8(-2-):U622-U631. >>> HU210; Tween; saline; SC; Mice; 2006; 6 weeks; Control animals received mp w/ vehicle; animal info (C57BL/6J, male, 9 wks old); HU210 is a potent agonist; functionality of mp verified via HPLC-HRMS in the brain tissue; stability verified (6 weeks, pg e55963).
Q2631 Morales-Medina,J.C., Dumont,Y., Bonaventure,P., Quirion,R. Chronic administration of the Y(2) receptor antagonist, JNJ-31020028, induced anti-depressant like-behaviors in olfactory bulbectomized rat. Neuropeptides 2012; 46(-6-):329-334. >>> JNJ-31020028; DMSO; saline; CSF/CNS; Rat; 2002; 14 days; Control animals received mp w/ saline; animal info (Sprague Dawley, male, 150-170 g, OBX); 1% DMSO used; stability verified (28 days) pg 330; JNJ-31020028 is a Y2 receptor antagonist.
Q2522 Yo,K., Yu,Y.M., Zhao,G.Z., Bonab,A.A., Aikawa,N., Tompkins,R.G., Fischman,A.J. Brown adipose tissue and its modulation by a mitochondria-targeted peptide in rat burn injury-induced hypermetabolism. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM 2013; 304(-4-):E331-E341. >>> SS31; Saline; IV (jugular); Rat; 7 days; Control animals received mp w/ vehicle; animal info (Sprague Dawley, male, 16-19 wks old, 400-500 g); peptides; stability verified via stable isotope dilution method ("more than 7 days").
Q2499 Zhu,X.X., Krasnow,S.M., Roth-Carter,Q.R., Levasseur,P.R., Braun,T.P., Grossberg,A.J., Marks,D.L. Hypothalamic signaling in anorexia induced by indispensable amino acid deficiency. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM 2012; 303(-12-):E1446-E1458. >>> SHU-9119; CSF/CNS; Rat; 2004; ; Control animals received mp w/ artificial CSF; animal info (Sprague Dawley, 7-8 wks old); ; brain infusion kit 2 used; stability verified (21 days, pg E1450).
Q2300 Kassel,K.M., Sullivan,B.P., Cui,W., Copple,B.L., Luyendyk,J.P. Therapeutic Administration of the Direct Thrombin Inhibitor Argatroban Reduces Hepatic Inflammation in Mice with Established Fatty Liver Disease. American Journal of Pathology 2012; 181(-4-):1287-1295. >>> Argatroban; Acetic acid, glacial; sodium acetate; PEG 400; SC; Mice; 2004; 4 weeks; Control animals received mp w/ vehicle; animal info (LDLr -/-, male, 6 wks old); 20% PEG 400 used; stability verified (4 weeks); post op. care (buprenorphine HCl).
Q2174 Simard,J.M., Woo,S.K., Tsymbalyuk,N., Voloshyn,O., Yurovsky,V., Ivanova,S., Lee,R., Gerzanich,V. Glibenclamide-10-h Treatment Window in a Clinically Relevant Model of Stroke. TRANSLATIONAL STROKE RESEARCH 2012; 3(-2-):286-295. >>> Glibenclamide; DMSO; saline; NaOH; SC; Rat; 2001; 48 hours; Controls received mp w/ vehicle; animal info (Wistar, male, 250-275 g); 5.5 hour delayed delivery accomplished by connecting 5.5 ul volume PE60; functionality of mp verified by residual volume; 8% DMSO used; stability verified via spectrophotometry; ischemia (cerebral).
Q2064 Bas,E., Van de Water,T.R., Gupta,C., Dinh,J., Vu,L., Martinez-Soriano,F., Lainez,J.M., Marco,J. Efficacy of three drugs for protecting against gentamicin-induced hair cell and hearing losses. British Journal of Pharmacology 2012; 166(-6-):1888-1904. >>> Gentamicin; dexamethasone; melatonin; Ear (round window); Rat; 2001; 7 days; Controls received mp w/ saline; animal info (Wistar, male, 220-250 g); stability verified after 7 days (data not shown).
Q1983 Yuan,Y., Kasar,S., Underbayev,C., Vollenweider,D., Salerno,E., Kotenko,S.V., Raveche,E. Role of microRNA-15a in autoantibody production in interferon-augmented murine model of lupus. MOLECULAR IMMUNOLOGY 2012; 52(-2-):61-70. >>> Interferon, alpha; interferon, gamma; PBS; BSA; SC; Mice; 2006; 16 weeks; Animal info (13 wks old, female, B/W); pumps replaced after 8 weeks; long-term study; stability verified after 8 weeks; "residue IFNs from the pumps at the end of treatment were tested on IFN and IFN responsive cell lines and demonstrated that the in vivo conditions in the pump did not affect bioactivity of both IFNs (data not shown)" pg 63.
Q1576 Pedersen,S.L., Sasikumar,P.G., Chelur,S., Holst,B., Artmann,A., Jensen,K.J., Vrang,N. Peptide hormone isoforms: N-terminally branched PYY3-36 isoforms give improved lipid and fat-cell metabolism in diet-induced obese mice. JOURNAL OF PEPTIDE SCIENCE 2010; 16(-11-):664-673. >>> Peptide YY (3-36); peptide YY (3-36), isoform 2; peptide YY (3-36), isoform 3; Saline; SC; Mice; 1003D; 2002; 3 days; Controls received mp w/ vehicle; animal info (male, DIO C57BL/6J, NMRI, 8-9 wks old); incorrectly listed Model 1003 pumps used; stability verified pg 667 (2, 7,. 14 days via HPLC); wound clips used.
Q1430 Liu,Y.L., Ford,H.E., Druce,M.R., Minnion,J.S., Field,B.C.T., Shillito,J.C., Baxter,J., Murphy,K.G., Ghatei,M.A., Bloom,S.R. Subcutaneous oxyntomodulin analogue administration reduces body weight in lean and obese rodents. International Journal of Obesity 2010; 34(-12-):1715-1725. >>> OXM6421; oxyntomodulin; Saline; SC; Rat; mice; 2001; 7 days; Controls received mp w/ vehicle; animal info (Wistar, male, 250-300 g; DIO, male); peptides; stability verified by HPLC (7 days); OXM6421 is a long-acting oxyntomodulin (OXM) analogue; obesity.
Q1165 Kim,J., Thorne,S.H., Sun,L., Huang,B., Mochly-Rosen,D. Sustained inhibition of PKC alpha; reduces intravasation and lung seeding during mammary tumor metastasis in an in vivo mouse model. ONCOGENE 2011; 30(-3-):323-333. >>> Peptide, TAT; peptide, alpha V5-3; pyrrolidine dithiocarbamate; antibody, anti-CXCR4; Saline; SC; Mice; 1002; 4 weeks; Animal info (BALB/c, 6 wks old, female); pumps replaced every 2 weeks; stability verified (2 weeks, pg 331); incorrectly listed using Model 2001; "Pumps were replaced every 2 weeks, which corresponds to the stability of the peptides in the pump." pg 331; bioluminescence IVIS100.
Q0707 Tange,Y., Miyazaki,M., Iwata,J., Aiko,Y., Sakamoto,S., Mori,K. Novel Antitumor Effect of Carboplatin Delivered by Intracerebral Microinfusion in a Rat Malignant Glioma Model. NEUROLOGIA MEDICO-CHIRURGICA 2009; 49(-12-):572-579. >>> Carboplatin; Glucose, D-; Evans blue; CSF/CNS (intratumoral); Rat; 2001; 3, 7 days; Animal info (male, F344/N Slc, Fischer 220-260 g); brain tissue distribution; ALZET brain infusion kit used; stability verified (4 weeks) pg 573; cancer (glioma); MRI; brain tissue distribution; "... continuous intracerebral microinfusion using the osmotic mini-pump can provide broader distribution of agents than growth of the brain tumor."; "intracerebral microinfusion can attain clinically favorable drug distribution from a single infusion point." pg 576.
Q0586 Dilda,P.J., Decollogne,S., Weerakoon,L., Norris,M.D., Haber,M., Allen,J.D., Hogg,P.J. Optimization of the Antitumor Efficacy of a Synthetic Mitochondrial Toxin by Increasing the Residence Time in the Cytosol. Journal of Medicinal Chemistry 2009; 52(-20-):6209-6216. >>> Phenylarsonous acid; PBS; SC; Mice (nude); 1004; ; Controls received mp w/ vehicle; animal info (BalbC, nude, Female 7-9 week old); stability verified in vitro for at least 2 weeks at 4 or 37 degrees C; "There was a small accumulation of connective tissue at the delivery site of the osmotic pump in 7 of the 10 mice at the higher dose of PENAO. This is likely the result of a local inflammatory response triggered by the high concentrations of PENAO at the delivery site." pg 6213; Phenylarsonous acid (PENAO) is a cysteine mimetic analogue of CAO; cancer.
Q0562 Bennett,S.P., Boyd,T.D., Norden,M., Padmanabhan,J., Neame,P., Wefes,I., Potter,H. A novel technique for simultaneous bilateral brain infusions in a mouse model of neurodegenerative disease. Journal of Neuroscience Methods 2009; 184(-2-):320-326. >>> Antichymotrypsin, alpha-1; CSF, artificial; CSF/CNS; CSF/CNS (hippocampal parenchyma); Mice; 1004; 28 days; Controls received mp w/ vehicle; animal info (PS/APP, PS/APP/ACT, 10 mo old); functionality of mp verified by residual volume; cyanoacrylate adhesive; multiple pumps per animal (2); stability verified ("minimal degradation" after 28 days); custom catheter solution for simultaneous bilateral brain infusions; nitrile cap used to affix custom catheters to the skull; pump plus custom catheter assembly Fig 3e; "entire catheters and pumps we used can be completely removed without terminating the life of the animal" pg 326; bilateral infusion;.
Q0450 Marino,P., Norreel,J.C., Schachner,M., Rougon,G., Amoureux,M.C. A polysialic acid mimetic peptide promotes functional recovery in a mouse model of spinal cord injury. Experimental Neurology 2009; 219(-1-):163-174. >>> PR-21; Water; Rat; 1007D; ; Animal info (9 wks old, female, Wistar); peptides; half-life (p. 166) approximately 14 days in vitro at 37 degrees C; stability verified by ELISA; PR-21 also known as PSA-mimetic peptide; "We verified that PR-21 remained stable in the vehicle (WFI) during 14 days." pg 166; spinal cord injury.
Q00258 Pathipati,P., Surus,A., Williams,C.E., Scheepens,A. Delayed and chronic treatment with growth hormone after endothelin-induced stroke in the adult rat. Behavioural Brain Research 2009; 204(-1-):93-101. >>> Growth hormone, rat; NaCl; tween 20; NaHCO3; Na2CO3; CSF/CNS; Rat; 2002; 6 weeks; Controls received mp w/ vehicleanimal info (adult, male, Sprague-Dawley, 280-350 g); pumps replaced every 2 weeks; stability verified by for 2 weeks in vitro.
Q00222 Campanella,C., Jamali,F. Influence of prolonged exposure of a short half life non-steroidal anti-inflammatory drugs on gastrointestinal safety. INFLAMMOPHARMACOLOGY 2009; 17(-4-):205-210. >>> Flurbiprofen; PEG 400; IP; Rat; 2002; 7 days; Comparison of IP injections vs. mp; stability verified in vitro test for 14 days; animal info (male, Sprague Dawley, adult, 300-350 g.); "There was no significant difference between the two i.p. groups in the post-mortem plasma R or S-flurbiprofen concentration or in the percent of the dose excreted as glucoronidated flurbiprofen in urine on days 1 and 7" pg 207.
P9867 Thakker,D.R., Weatherspoon,M.R., Harrison,J., Keene,T.E., Lane,D.S., Kaemmerer,W.F., Stewart,G.R., Shafer,L.L. Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2009; 106(-11-):4501-4506. >>> Immunoglobulin G1; 6E10; CSF/CNS; Mice (transgenic); 2004; ; Functionality of mp verified in vitro for 5 weeks; stability verified in vitro for 5 weeks; animal info (male, 16-18 months old, Tg2576); neurodegenerative (Alzheimer's Disease); 6E10 is a mouse monoclonal IgG1; brain tissue distribution.
P9790 Joosen,M.J.A., Jousma,E., van den Boom,T.M., Kuijpers,W.C., Smit,A.B., Lucassen,P.J., Van Helden,H.P.M. Long-term cognitive deficits accompanied by reduced neurogenesis after soman poisoning. Neurotoxicology 2009; 30(-1-):72-80. >>> Olanzapine; Acetic acid, glacial; SC; Rat; 2ML4; 4 weeks; Functionality of mp verified by residual volume; animal info (male, Sprague Dawley); stability verified for 4 weeks by electrospray MS/MS.
P9766 Mueller,M.C., Osswald,M., Tinnes,S., Haeussler,U., Jacobi,A., Foerster,E., Frotscher,M., Haas,C.A. Exogenous reelin prevents granule cell dispersion in experimental epilepsy. Experimental Neurology 2009; 216(-2-):390-397. >>> Reelin, recomb.; CSF/CNS (hippocampus); Mice; 2002; 2 weeks; Negative controls received mp w/saline; stability verified by western blot analysis (2 wks); brain tissue distribution; ALZET brain infusion kit 3 used; animal info (C57BL/6NCrI, male, 8-10 wks old); reelin is an extracellular matrix protein important for neuronal positioning.
P9632 Ortiz,M.A., Campana,G.L., Woods,J.R., Boguslawski,G., Sosa,M.J., Walker,C.L., Labarrere,C.A. Continuously-infused Human C-Reactive Protein Is Neither Proatherosclerotic Nor Proinflammatory in Apolipoprotein E-Deficient Mice. EXPERIMENTAL BIOLOGY AND MEDICINE 2009; 234(-6-):624-631. >>> C-reactive protein, human; IP; Mice; 2004; 28 days; Controls received mp w/placebo solution; stability verified by non-denaturing Western blotting; animal info (apoE -/-, male, 12 wks old), IP catheter used.
P9513 Harvey,P.A., Lee,D.H.S., Qian,F., Weinreb,P.H., Frank,E. Blockade of Nogo Receptor Ligands Promotes Functional Regeneration of Sensory Axons after Dorsal Root Crush. Journal of Neuroscience 2009; 29(-19-):6285-6295. >>> Nogo receptor, soluble fragment; CSF/CNS; Rat; 2004; 28 days; Controls received mp w/ vehicle; stability verified by "separate tests" (up to 1 month, pg 6286); ALZET brain infusion kit 2 used; peptides; animal info (male, Sprague Dawley, 200-250 g.); sNGR.
P9487 Bloch-Shilderman,E., Rabinovitz,I., Egoz,I., Raveh,L., Allon,N., Grauer,E., Gilat,E., Weissman,B.A. Subchronic-exposure to low-doses of the nerve agent VX: Physiological, behavioral, histopathological and neurochemical studies. TOXICOLOGY AND APPLIED PHARMACOLOGY 2008; 231(-1-):17-23. >>> VX; Propylene glycol; SC; Rat; 2004; 1, 3 months; Controls received mp w/ vehicle; pumps replaced every 10 days; no stress (see pg. 19); stability verified by AChE inhibition in vitro @ -20, 25, 38 degrees Celsius @ 24h, 48h, and 1 week; animal info (male, Sprague Dawley, 260-300 g.); VX, a nerve agent, also known as O-ethyl-S-(isoporopylaminoethyl) methyl phosphonothiolate; toxic organophosphorous; "when pumps were replaced the new incision was made in an adjacent dorsal area." pg. 18; enzyme inhibitor (ACE); long-term study.
P9416 Isa,K., Garcia-Espinosa,M.A., Arnold,A.C., Pirro,N.T., Tommasi,E.N., Ganten,D., Chappell,M.C., Ferrario,C.M., Diz,D.I. Chronic immunoneutralization of brain angiotensin-(1-12) lowers blood pressure in transgenic (mRen2) 27 hypertensive rats. American Journal of Physiology-Regulatory Integrative and Comparative Physiology 2009; 297(-1-):R111-R115. >>> Antibody, rabbit anti-rat ANG (1-12); immunoglobulin G, rabbit; CSF, artificial; CSF/CNS; Rat (transgenic); 2ML2; 14 days; Controls received mp w/ IgG; functionality of mp verified by residual volume; no stress (see pg. R111, R112); stability verified by activity of agent in residual volume, 91-98% on day 13; antihypertensive; ALZET brain infusion 2 kit; animal info (male, (mRen2)27 Tg, 22-28 wks old, 550g.); cannula placement confirmed at end of each study.
P9248 Poesen,K., Lambrechts,D., Van Damme,P., Dhondt,J., Bender,F., Frank,N., Bogaert,E., Claes,B., Heylen,L., Verheyen,A., Raes,K., Tjwa,M., Eriksson,U., Shibuya,M., Nuydens,R., Van den Bosch,L., Meert,T., D'Hooge,R., Sendtner,M., Robberecht,W., Carmeliet,P. Novel Role for Vascular Endothelial Growth Factor (VEGF) Receptor-1 and Its Ligand VEGF-B in Motor Neuron Degeneration. Journal of Neuroscience 2008; 28(-42-):10451-10459. >>> Vascular endothelial growth factor-B186, recomb. mouse; CSF, artificial; CSF/CNS; Rat; 2004; 100 days; Controls received mp w/ vehicle; long-term study; pumps replaced every 25 days; no stress (see pg. 10456); stability verified by 4 weeks in mp at 37 degrees Celsius; animal info (HAN-Wistar x Sprague Dawley-hSOD1G93A, 60 days old); behavioral testing (Rotarod test); "this delivery route was chosen because previous studies demonstrated that intracerebroventricularly delivered VEGF diffuses from the CSF into the neural parenchyma, where it reaches it's target motor neurons." (p. 10456).
P9237 Galvao,R.P., Garcia-Verdugo,J.M., varez-Buylla,A. Brain-Derived Neurotrophic Factor Signaling Does Not Stimulate Subventricular Zone Neurogenesis in Adult Mice and Rats. Journal of Neuroscience 2008; 28(-50-):13368-13383. >>> Ara-C; brain-derived neurotrophic factor; Saline; BSA; CSF/CNS; Rat; mice; 1007D; 2002; 6, 14 days; Controls received mp w/ vehicle; functionality of mp verified by weight loss due to BDNF's appetite suppression (p. 13377), residual volume; stability verified by testing activity of residual BDNF volume after 14 days/37 degrees Celsius; brain tissue distribution; peptides; post op. care (Buprenorphine); animal info (male, Sprague Dawley, 250 g., male CD-1 3 mo old); mp/cannula placement visually confirmed after brain sectioning.
P9209 Ohta,Y., Kamiya,T., Nagai,M., Nagata,T., Morimoto,N., Miyazaki,K., Murakami,T., Kurata,T., Takehisa,Y., Ikeda,Y., Asoh,S., Ohta,S., Abe,K. Therapeutic benefits of intrathecal protein therapy in a mouse model of amyotrophic lateral sclerosis. Journal of Neuroscience Research 2008; 86(-13-):3028-3037. >>> TAT-GFP; TAT-Bcl-XL; CSF, artificial; CSF/CNS (intrathecal); Mice; mice (transgenic); 2001; 2004; 7, 28 days; Controls received mp w/ vehicle; stability verified by antiapoptotic effect at 7, 14, and 28 days at 37 degree Celsius (p. 3031); peptides; animal info (male, B6SJL, wt, G93A SOD1 Tg, 91 days old); neurodegenerative (ALS); behavioral testing (Rotarod test, wheel running test); "intrathecal infusion of TAT-infused proteins using an osmotic minipump is a better method of delivering therapeutic proteins into the spinal cord." (p. 3035).
P8979 Susic,D., Zhou,X.Y., Frohlich,E.D., Lippton,H., Knight,M. Cardiovascular effects of prorenin blockade in genetically spontaneously hypertensive rats on normal and high-salt diet. American Journal of Physiology-Heart and Circulatory Physiology 2008; 295(-3-):H1117-H1121. >>> PRAM-1; Water, distilled; SC; Rat; 2ML4; 4, 8 weeks; Controls received mp w/ vehicle; long-term study; pumps replaced after 4 weeks; stability verified; cardiovascular; peptides; animal info (male, SHR, 20 wks old); PRAM-1 is a custom synthesized prorenin inhibitor; "no degradation products of the peptide were observed".
P8928 Tejeda,M., Gaal,D., Hullan,L., Csuka,O., Schwab,R., Szokolocz,O., Keri,G. A comparison of the tumor growth inhibitory effect of intermittent and continuous administration of the somatostatin structural derivative TT-232 in various human tumor models. Anticancer Research 2006; 26(-4B-):3011-3015. >>> TT-232; Water, distilled; acetic acid; sodium acetate; mannitol; SC; Mice (SCID); 2002; 14, 28 days; Comparison of IP, SC injections vs. SC mp; stability verified by 3 weeks at 37 degree Celsius by HPLC analysis for agent + degradation products; cancer (epidermoid carcinoma, breast carcinoma); peptides; animal info (female, SCID, 22-24 g.); somatostate structural derivative; "The comparative experiments (injection and infusion) confirmed that continuous treatments and long-term administration were associated with the best treatment responses" (p. 3014); "Continuous infusion administration of TT-232 significantly inhibited the growth of the tumor when compared with intraperitoneal (ip) and subcutaneous (sc) intermittent injection treatments." (p. 3011).
P8852 Wang,H.Y., Ghosh,A., Baigude,H., Yang,C.S., Qiu,L.H., Xia,X.G., Zhou,H.X., Rana,T.M., Xu,Z.S. Therapeutic gene silencing delivered by a chemically modified small interfering RNA against mutant SOD1 slows amyotrophic lateral sclerosis progression. Journal of Biological Chemistry 2008; 283(-23-):15845-15852. >>> RNA, small interfering, modified; RNA, small interfering; PBS; CSF/CNS (intrathecal, subarachnoid space); Mice (transgenic); 1007D; 2004; 7, 28 days; 72 hours; Controls received mp w/ vehicle; functionality of mp verified by residual volume; dose-response (Fig. 3); no stress (see pg. 15846, 15849); stability verified by 28 days in vivo (see Fig. 2); half-life (p. 15846) "short"; gene therapy; brain tissue distribution; animal info (SOD1G93A Tg); neurodegenerative (ALS); mp + catheter positioning confirmed; Target (SOD1); "when infused at disease onset at the therapeutic dose for 4 weeks, this siRNA slows disease progression without detectable adverse effects." The catheter was implanted between the L5 and L6 vertebra and connected to a primed Alzet osmotic pump with the PE50 tube. The catheter was stitched to the surface muscle, and the Alzet osmotic pumps were placed under the skin on the back of the mouse..
P8775 Roa,J., Vigo,E., Garcia-Galiano,D., Castellano,J.M., Navarro,V.M., Pineda,R., Dieguez,C., Aguilar,E., Pinilla,L., Tena-Sempere,M. Desensitization of gonadotropin responses to kisspeptin in the female rat: analyses of LH and FSH secretion at different developmental and metabolic states. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM 2008; 294(-6-):E1088-E1096. >>> Kisspeptin-10; Leptin; Saline, physiological; CSF/CNS; Rat; 2001; 7 days; Controls received mp w/ vehicle; functionality of mp verified by response duration and examination; stability verified by persistent FSH response; peptide; animal info (female, Wistar, 205-275 g., adult, 110-120g., 30 days old).
P8639 Palaniyandi,S.S., Nagai,Y., Watanabe,K., Ma,M., Veeraveedu,P.T., Prakash,P., Kamal,F.A., Abe,Y., Yamaguchi,K., Tachikawa,H., Kodama,M., Aizawa,Y. Chymase inhibition reduces the progression to heart failure after autoimmune myocarditis in rats. EXPERIMENTAL BIOLOGY AND MEDICINE 2007; 232(-9-):1213-1221. >>> TY-51469; Phosphate buffer; NaOH; IV (jugular); Rat; 2ML4; 4 weeks; Controls received mp w/ vehicle; dose-response (fig. 2); stability verified by study in rat plasma at 40oC for 1 hour; enzyme inhibitor (chymase); cardiovascular; animal info (male, Lewis, 9 wks old).
P8606 Hagg,T., Baker,K.A., Emsley,J.G., Tetzlaff,W. Prolonged local neurotrophin-3 infusion reduces ipsilateral collateral sprouting of spared corticospinal axons in adult rats. Neuroscience 2005; 130(-4-):875-887. >>> Neurotrophin-3, recomb. human; PBS; gentamicin; albumin, rat serum; CSF/CNS (intrathecal); Rat; 2002; 14 days; Controls received mp w/ vehicle; functionality of mp verified by residual volume; dose-response (fig. 4); stability verified by activity assay of residual mp content after 14 days in vivo; ALZET brain infusion kit used; peptides; post op. care (Penicillin G, buprenorphine); animal info (Sprague-Dawley, 3 months old, 200-220 grams, partial resection of corticospinal tract); schematic of mp p. 877 fig 2.
P8437 Henke,E., Perk,J., Vider,J., de Candia,P., Chin,Y., Solit,D.B., Ponomarev,V., Cartegni,L., Manova,K., Rosen,N., Benezra,R. Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo. NATURE BIOTECHNOLOGY 2008; 26(-1-):91-100. >>> Oligonucleotide, antisense, peptide conjugated; oligonucleotide, phosphorothioate antisense; peptide, F3; TBS; SC; Mice (nude); mice; 1007D; 1002; 14, 21 days; Controls received mp w/ vehicle or control peptide and oligo in non-conjugated form, or rcId1-PCAO; comparison of IV injections vs. mp; pumps replaced after 14 days; no stress (see pg. 95, 97); stability verified after 24 hours in 37 C, plasma up to 28 days in 37 C saline; antisense (Id1, rcId1); cancer (breast, lung carcinoma); peptides; toxicology; animal info (female, nude NCR; male, C57J/B6); antisense oligos covalently coupled to address peptide that targets tumor endothelial cells; "no adverse effects on treated mice have been observed." (p. 97).
P8419 Jiang,G.L., Nieves,A., Im,W.B., Old,D.W., Dinh,D.T., Wheeler,L. The prevention of colitis by E prostanoid receptor 4 agonist through enhancement of epithelium survival and regeneration. Journal of Pharmacology and Experimental Therapeutics 2007; 320(-1-):22-28. >>> AGN205203; DMSO; saline, normal; SC; Mice; 1002; 9 days; Controls received mp w/ vehicle; metabolic&chemical stability verified; animal info (femal, C57BL/6, 8 wks old); EP4 agonist.
P8406 Zeevalk,G.D., Manzino,L., Sonsalla,P.K., Bernard,L.P. Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: Relevance to Parkinson's disease. Experimental Neurology 2007; 203(-2-):512-520. >>> Glutathione, monoethyl ester; MPP+; Saline; SC; CSF/CNS; Rat; 2ML4; 28 days; Controls received mp w/ vehicle; dose-response (fig. 6); stability verified by incubation for 0-28 days at 37 celsius, assessed by HPLC; half-life (pg. 515) 10-14 hours in culture; brain tissue distribution; toxicology; animal info (Sprague-Dawley, 300g.); neurodegenerative (Parkinson's disease).
P8305 Mook,O.R., Baas,F., de Wissel,M.B., Fluiter,K. Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo. MOLECULAR CANCER THERAPEUTICS 2007; 6(-3-):833-843. >>> RNA, small interfering; RNA, small interfering, LNA-modified; Radio-isotopes, 3H-; SC; Mice (nude); 1007D; 7 days; 48 hours; Controls received mp w/ mismatch siRNA or saline; comparison of IV injections vs. mp; stability verified by incubation in mouse serum; half-life (p. 837) increased in LNA-modified; unmodified completely degraded in<5 hours; cancer (pancreatic); animal info (NMRI nu/nu, 8-10 weeks old); siRNA against RNA polymerase II, enhanced GFP, or mismatch.
P8302 Zhang,X.F., Connolly,C., Duquette,M., Lawler,J., Parangi,S. Continuous administration of the three thrombospondin-1 type 1 repeats recombinant protein improves the potency of therapy in an orthotopic human pancreatic cancer model. Cancer Letters 2007; 247(-1-):143-149. >>> Thrombospondin-1, three type 1 repeats; PBS; SC; Mice (SCID); 1007D; 7 days; Controls received mp w/ vehicle; comparison of IP injections vs. mp; stability verified by incubation in pump, 7 days; cancer (pancreatic); peptides; animal info (female, SCID, 4-6 weeks old); antiangiogenesis therapy; 3TSR; "Continuous administration of 3TSR reduced dosage and improved therapeutic potency." p. 146.
P8289 Banach-Petrosky,W., Ouyang,X.S., Gao,H., Nader,K., Ji,Y., Suh,N., DiPaola,R.S., bate-Shen,C. Vitamin D inhibits the formation of prostatic intraepithelial neoplasia in Nkx3.1; Pten mutant mice. Clinical Cancer Research 2006; 12(-19-):5895-5901. >>> Vitamin D3, 1,25-dihydroxy-; Propylene glycol; SC; Mice; 2004; 1-4 months; Controls received mp w/ vehicle; long-term study; pumps replaced every 4 weeks; stability verified by serum calcium levels; cancer (prostate); animal info (4-7 months old, male).
P8284 Yazdani,U., German,D.C., Liang,C.L., Manzino,L., Sonsalla,P.K., Zeevalk,G.D. Rat model of Parkinson's disease: Chronic central delivery of 1-methyl-4-phenylpyridinium (MPP+). Experimental Neurology 2006; 200(-1-):172-183. >>> MPP+; Saline-iodine; CSF/CNS; Rat; 2ML4; 14 days; Stability verified by HPLC, 28 days; animal info (male, Sprague-Dawley, 300-350 grams); neurodegenerative (Parkinson's Disease); "This study presents a chronic model of PD in rats that encompasses the desirable components of current chronic models while reducing their less desirable aspects." P. 181.
P8266 Urushitani,M., bou Ezzi,S., Julien,J.P. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2007; 104(-7-):2495-2500. >>> Antibody, mouse anti hSOD1; antibody, rabbit polyclonal anit-hSOD1-FITC; Saline; CSF/CNS; Mice; 2004; 16, 28 days; Controls received mp w/ vehicle; functionality of mp verified by residual volume; stability verified by Western Blot w/ residual volume AB after 18 days infusion; brain tissue distribution; animal info (G93A SOD1, 85 days old); neurodegenerative (ALS).
P8236 Lecanu,L., Greeson,J., Papadopoulos,V. Beta-amyloid and oxidative stress jointly induce neuronal death, amyloid deposits, gliosis, and memory impairment in the rat brain. Pharmacology 2006; 76(-1-):19-33. >>> Amyloid protein, beta 42; ferrous sulfate; buthionine sulfoximine; CSF, artificial; water, distilled; CSF/CNS; Rat; 2ML4; 4 weeks; Controls received mp w/ vehicle; stability verified by 14 days in mp at 37 C; animal info (male, Long-Evans, 3-4 month old, 300-325 grams); neurodegenerative (Alzheimer's disease).
P8145 Grommes,C., Landreth,G.E., Sastre,M., Beck,M., Feinstein,D.L., Jacobs,A.H., Schlegel,U., Heneka,M.T. Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment. MOLECULAR PHARMACOLOGY 2006; 70(-5-):1524-1533. >>> Pioglitazone; DMSO; PBS; CSF/CNS (intratumoral); Rat; 2ML4; 3, 6, 9, 14, 21 days; Controls received mp w/ vehicle; comparison of oral admin. vs. mp; no stress (see p.1532); stability verified by in vitro incubation at 37 celsius for 21 days; cancer (glioma); ALZET brain infusion kit used; animal info (Sprague-Dawley, 200-250g.); 0.1% DMSO; Antineoplastic; tissue perfusion (tumor).
P8096 Gosain,A., Matthies,A.M., Dovi,J.V., Barbul,A., Gamelli,R.L., DiPietro,L.A. Exogenous pro-angiogenic stimuli cannot prevent physiologic vessel regression. Journal of Surgical Research 2006; 135(-2-):218-225. >>> Vascular endothelial growth factor 164, recomb.; platelet-dreived growth factor; fibroblast growth factor-2; Wound site; Mice; 2002; 11 days; Controls received mp w/ PBS; functionality of mp verified by VEGF levels in wound sponges, residual volume; stability verified by activity of residual VEGF in endothelial cell cord formation assay (fig.4); cardiovascular; peptides; animal info (female, BALB/c, 8-9 wks old, implanted sponge wounds); "The activity of VEGF isolated from the pump was comparable to fresh recombinant VEGF 164, confriming that the recombinant growth factors present in the mini-osmotic pump retain robust biological activity." (p.221).
P8052 Brown,J.R., Fuster,M.M., Li,R.X., Varki,N., Glass,C.A., Esko,J.D. A disaccharide-based inhibitor of glycosylation attenuates metastatic tumor cell dissemination. Clinical Cancer Research 2006; 12(-9-):2894-2901. >>> Disaccharide, AcGnG-NM; DMSO; propylene glycol; SC; Mice; 2004; 2, 4 weeks; Controls received mp w/ vehicle; stability verified by incubation in mouse serum; cancer (lung carcinoma, B16Bl6 melanoma); animal info (c57BL/6 Es1(e); 8-12 wk old, lung metastases); 50% DMSO used; 50% propylene glycol used.
P8015 Vrang,N., Madsen,A.N., Tang-Christensen,M., Hansen,G., Larsen,P.J. PYY(3-36) reduces food intake and body weight and improves insulin sensitivity in rodent models of diet-induced obesity. Am.J.Physiol Regul.Integr.Comp Physiol 2006/8; 291(-2-):R367-R375. >>> Peptide YY (3-36); Saline, isotonic; SC; Mice; rat; 2004; 2ML4; 28 days; Stability verified by in vitro test, degradation was<0.5%/day; peptides; animal info (C57BL/6, DIO and rats, Wistar and Sprague-Dawley); gut hormone; SC administration of PYY (3-36) for 28 days reduced body weight and improved glycemic control.
P7973 Bartolomucci,A., La Corte,G., Possenti,R., Locatelli,V., Rigamonti,A.E., Torsello,A., Bresciani,E., Bulgarelli,I., Rizzi,R., Pavone,F., D'Amato,F.R., Severini,C., Mignogna,G., Giorgi,A., Schinina,M.E., Elia,G., Brancia,C., Ferri,G.L., Conti,R., Ciani,B., Pascucci,T., Dell'Omo,G., Muller,E.E., Levi,A., Moles,A. TLQP-21, a VGF-derived peptide, increases energy expenditure and prevents the early phase of diet-induced obesity. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2006; 103(-39-):14584-14589. >>> TLQP-21, synthetic; CSF, artificial; CSF/CNS; Mice; 1002; 14 days; Controls received mp w/ vehicle; stability verified by HPLC after 14 days at 37 C; ALZET brain infusion kit 1 used; peptides; animal info (male, CD1); obesity.
P7942 Berni,R., Cacciani,F., Zaniboni,M., Savi,M., Bocchi,L., Lapucci,S., Razzetti,R., Pastore,F., Musso,E., Stilli,D. Effects of the alpha 2-adrenergic/DA2-dopaminergic agonist CHF-1024 in preventing ventricular arrhythmogenesis and myocyte electrical remodeling, in a rat model of pressure-overload cardiac hypertrophy. Journal of Cardiovascular Pharmacology 2006; 47(-2-):295-302. >>> CHF-1024; Saline; ascorbic acid; SC; Rat; 2ML4; 1 month; Controls received mp w/ vehicle; functionality of mp verified by plasma levels; dose-response (table 1); stability verified for at least 1 month (pg. 296); cardiovascular; post op. care (gentamicin); animal info (male, Wistar, 6 months old); "a clear dose dependency was found in CHF-1024 plasma levels, indicating a good performance of the osmotic pumps in drug release." (p. 299).
P7900 Thompson,E.L., Murphy,K.G., Patterson,M., Bewick,G.A., Stamp,G.W.H., Curtis,A.E., Cooke,J.H., Jethwa,P.H., Todd,J.F., Ghatei,M.A., Bloom,S.R. Chronic subcutaneous administration of kisspeptin-54 causes testicular degeneration in adult male rats. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM 2006; 291(-5-):E1074-E1082. >>> Kisspeptin-54; Saline; SC; Rat; 2001D; 2001; 2002; 1, 2, 3, 13 days; Controls received mp w/ vehicle; functionality of mp verified by residual volume; comparison of SC injection vs. mp; no stress (see pg. E1078); stability verified by 14 days in mp in 37 celsius saline (see fig. 2); good methods pg. E1075; peptides; post op. care (flucloxacillin, amoxicillin); animal info (male, Wistar, 275-325g.); mp primed for 3hrs. (2001D) or overnight (2001, 2002) in 37 celsius saline; "animals were healthy throughout the study period. No adverse behaviors were observed in any of the treatment groups at any point during the study." (pg. E1078).
P7844 Royo,N.C., Conte,V., Saatman,K.E., Shimizu,S., Belfield,C.M., Soltesz,K.M., Davis,J.E., Fujimoto,S.T., McIntosh,T.K. Hippocampal vulnerability following traumatic brain injury: a potential role for neurotrophin-4/5 in pyramidal cell neuroprotection. European Journal of Neuroscience 2006; 23(-5-):1089-1102. >>> Neurotrophin-4/5; PBS; BSA; CSF/CNS (somatosensory cortex); Rat; 1007D; 1 week; Controls received mp w/ vehicle; no stress (see pg. 1095); stability verified by activity after 14 days in mp at 37 celsius; ALZET brain infusion kit II used; peptides; animal info (male, Sprague-Dawley, 350-400g., traumatic brain injury by lateral fluid percussion); mp primed 18 hours at 37 celsius.
P7843 Yamaguchi,Y., Miyashita,H., Tsunekawa,H., Mouri,A., Kim,H.C., Saito,K., Matsuno,T., Kawashima,S., Nabeshima,T. Effects of a novel cognitive enhancer, spiro[imidazo[1,2-a]pyridine-3,2- indan]-2(3H)-one (ZSET1446), on learning impairments induced by amyloid-beta (1-40) in the rat. Journal of Pharmacology and Experimental Therapeutics 2006; 317(-3-):1079-1087. >>> Amyloid protein, beta (1-40); amyloid protein, beta (40-1); Acetonitrile; trifluoroacetic acid; CSF/CNS; Rat; 2002; 15 days; Controls received mp w/ vehicle, or AB (40-1); stability verified by testing in solution at 37 celsius (pg. 1080); neurodegenerative (alzheimer's disease); animal info (male, Wistar, 7 wk. old); "An animal model induced by chronic intracerebroventricular (i.c.v.) infusion of AB is particularly attractive for evaluation of drugs for AD because change is similar to those known for AD patients" (pg. 1080); 35% acetonitrile used.
P7817 Igwe,O.J. Agents that act by different mechanisms modulate the activity of protein kinase C beta II isozyme in the rat spinal cord during peripheral inflammation. Neuroscience 2006; 138(-1-):313-328. >>> L-703606 oxalate; dextrorphan tartrate; oligodeoxynucleotide, phosporothioate antisense; phosporothioate missense; Propylene glycol; water, sterile; saline; oligofectamine; SC; Rat; 2001; 7 days; Controls received mp w/ vehicle; dose-response (fig 1); stability verified; antisense (protein kinase C, beta); animal info (male, Sprague-Dawley, 200-300 grams); "mini osmotic pumps were used to administer all agents in order to reduce animal handling after CFA-induced inflammation." (p. 315).
P7757 Winaver,J., Ovcharenko,E., Rubinstein,I., Gurbanov,K., Pollesello,P., Bishara,B., Hoffman,A., Abassi,Z. Involvement of Rho kinase pathway in the mechanism of renal vasoconstriction and cardiac hypertrophy in rats with experimental heart failure. American Journal of Physiology-Heart and Circulatory Physiology 2006; 290(-5-):H2007-H2014. >>> Y-27632; Saline; IP; Rat; 2001; 7 days; Controls received mp w/ vehicle; stability verified by assesment in saline and plasma at 37celsius for up to 500 min.; enzyme inhibitor (Rho Kinase); cardiovascular; animal info (male, Wistar, 280-350g., CHF).
P7563 Ikegami,T., Nakamura,M., Yamane,J., Katoh,H., Okada,S., Iwanami,A., Watanabe,K., Ishii,K., Kato,F., Fujita,H., Takahashi,T., Okano,H.J., Toyama,Y., Okano,H. Chondroitinase ABC combined with neural stem/progenitor cell transplantation enhances graft cell migration and outgrowth of growth-associated protein-43-positive fibers after rat spinal cord injury. European Journal of Neuroscience 2005; 22(-12-):3036-3046. >>> Chondroitinase ABC; Saline, physiological; CSF/CNS (intrathecal, subarachnoid space); Rat; 2001; 1 week; Controls received mp w/ heat inactivated agent; stability verified by ALZAID chemical compability test kit for 7 days; animal info (adult, female, Sprague-Dawley 230-250 g); mp primed overnight in 37 C saline; spinal cord injury.
P7529 Tanaka,K., Takemoto,T., Sugahara,K., Okuda,T., Mikuriya,T., Takeno,K., Hashimoto,M., Shimogori,H., Yamashita,H. Post-exposure administration of edaravone attenuates noise-induced hearing loss. European Journal of Pharmacology 2005; 522(-1-3-):116-121. >>> Edaravone; saline; Water; NaOH; Ear (cochlea); Guinea-pig; 2002; 12 hours; Controls received no treatment to left ear; pumps replaced, mp w/ saline used then replaced with mp with agent; stability verified for 24 hours; post op. care (antibiotic ointment); animal info (male, Hartley, 300-450 g); tissue perfusion (cochlea).
P7519 Kennedy,D.J., Vetteth,S., Periyasamy,S.M., Kanj,M., Fedorova,L., Khouri,S., Kahaleh,M.B., Xie,Z.J., Malhotra,D., Kolodkin,N.I., Lakatta,E.G., Fedorova,O.V., Bagrov,A.Y., Shapiro,J.I. Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy. Hypertension 2006; 47(-3-):488-495. >>> Marinobufagenin; Rat; 2004; 4 weeks; Controls received sham operation; functionality of mp verified by agent plasma levels; comparison of partial nephrectomy vs. mp; stability verified for 4 weeks at 37 C by comparable inhibition of 86Rb uptake; cardiovascular; animal info (male, Sprague-Dawley).
P7500 Lotinun,S., Sibonga,J.D., Turner,R.T. Evidence that the cells responsible for marrow fibrosis in a rat model for hyperparathyroidism are preosteoblasts. Endocrinology 2005; 146(-9-):4074-4081. >>> Parathyroid hormone, human 1-34; thymidine, methyl -3H; Sodium chloride; HCl; serum, rat; ethanol; SC; Rat; 1, 2, 4 weeks; 1, 3, 5 days; Controls received mp w/ vehicle; functionality of mp verified by serum PTH; pumps replaced after 2 weeks; stability verified; peptides; multiple pumps per animal (2); animal info (female, Sprague-Dawley, 260 g); 2% ethanol.
P7497 Elitok,S., Brodsky,S.V., Patschan,D., Orlova,T., Lerea,K.M., Chander,P., Goligorsky,M.S. Cyclic arginine-glycine-aspartic acid peptide inhibits macrophage infiltration of the kidney and carotid artery lesions in apo-E-deficient mice. American Journal of Physiology-Renal Physiology 2006; 290(-1-):F159-F166. >>> Peptide, CRGD; peptide, CRAD; SC; Mice; 1002; 2004; 14, 28 days; Controls received mp w/ PBS; functionality of mp verified by platelet aggregation inhibitory properties and residual volume; dose-response (fig. 3); stability verified by mass spec of residual volume; half-life (p. F160); peptides; animal info (female, C57BL6, 7 weeks, 290 g); cartoid artery ligation.
P7467 Oldroyd,S.D., Miyamoto,Y., Moir,A., Johnson,T.S., El Nahas,A.M., Haylor,J.L. An IGF-I antagonist does not inhibit renal fibrosis in the rat following subtotal nephrectomy. American Journal of Physiology-Renal Physiology 2006; 290(-3-):F695-F702. >>> Insulin-like growth factor I, receptor antagonist; SC; Rat; 2002; 2004; 10, 90 days; Controls received mp w/ vehicle, or sham operation; dose-response (fig. 3); long-term study; pumps replaced every 4 weeks; stability verified by storage in mp for 4 weeks; peptides; animal info (male, wistar, chronic kidney disease, 200-300 g); IGF-I receptor antagonist (JB3); mp primed 4 hr in 37C isotonic saline.
P7394 Guarnieri,M., Carson,B.S., Khan,A., Penno,M., Jallo,G.I. Flexible versus rigid catheters for chronic administration of exogenous agents into central nervous system tissues. Journal of Neuroscience Methods 2005; 144(-2-):147-152. >>> Doxorubicin; carboblatin; Dextrose solution; saline; CSF/CNS (parenchyma); Rat; 2001; ; Animal info (F, Fischer, 220 g); Functionality of mp verified by pump examination, post infusion; stability verified by previous studies, 14 days; good methods (p. 148); cancer (glioma); brain tissue distribution; Plastics One cannula used (stainless steel); "replacement of rigid infusion tubes [cannulae] with flexible tubing increases the reliability of local CNS drug infusions. Rigid catheters [cannulae] may allow backflow of the infused drug along the path of the catheters into the subdural space." (P. 147).
P7267 Fluiter,K., Frieden,M., Vreijling,J., Rosenbohm,C., de Wissel,M.B., Christensen,S.M., Koch,T., Orum,H., Baas,F. On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide. CHEMBIOCHEM 2005; 6(-6-):1104-1109. >>> Oligodeoxynucleotide, antisense; oligodeoxynucleotide, amino-LNA antisense; oligodeoxynucleotide, thio-LNA antisense; oligodeoxynucleotide, LNA antisense; oligodeoxynucleotide, missense; SC; Mice (nude); 1002; 11 days; 48 hours; Controls received mp w/ saline; dose-response (fig. 4); no stress (see pg. 1106); stability verified by incubation in human serum; antisense (H-Ras); cancer (prostate).
P7265 Ji,B.X., Li,M.W., Budel,S., Pepinsky,R.B., Walus,L., Engber,T.M., Strittmatter,S.M., Relton,J.K. Effect of combined treatment with methylprednisolone and soluble Nogo-66 receptor after rat spinal cord injury. European Journal of Neuroscience 2005; 22(-3-):587-594. >>> Nogo-66 receptor (27-310) ecto-Fc; immunoglobulin G, rat; PBS; CSF/CNS (intrathecal); Rat; 2004; 28 days; Controls received mp w/ vehicle rat IgG; functionality of mp verified by residual volume; stability verified by analysis of remaining mp contents; post op. care (buprenorphine/buprenex, ampicillin); spinal cord injury.
P7264 Boesen,E.I., Anderson,W.P., Kett,M.M. Role of endothelin in noradrenaline-induced hypertension in rats. Journal of Hypertension 2005; 23(-5-):987-993. >>> Noradrenalin; TAK-044; heparin; Saline, heparinized; ascorbic acid; saline; IV (vena cava); Rat; 2ML2; 24 days; Controls received mp w/ vehicle; functionality of mp verified by residual volume; dose-response (fig. 2); pumps replaced at day 10; no stress (see pg. 989); stability verified by acute pressor activity after 14 days at 37 degrees celsius in mp; cardiovascular; multiple pumps per animal (2); 10 IU/ml of heparin.
P7137 Baker,S.A., Baker,K.A., Hagg,T. D3 dopamine receptors do not regulate neurogenesis in the subventricular zone of adult mice. NEUROBIOLOGY OF DISEASE 2005; 18(-3-):523-527. >>> DPAT, 7-hydroxy-U-99194A maleate; Saline; CSF/CNS; CSF/CNS (neostriatum); Rat; mice; 1002; 14 days; Controls received mp w/ vehicle; dose-response; comparison of IP injections vs. mp; stability verified by BrdU labeling; cyanoacrylate adhesive used.
P7099 Benn,S.C., Ay,I., Bastia,E., Chian,R.J., Celia,S.A., Pepinsky,R.B., Fishman,P.S., Brown,RH Jr, Francis,J.W. Tetanus toxin fragment C fusion facilitates protein delivery to CNS neurons from cerebrospinal fluid in mice. Journal of Neurochemistry 2005; 95(-4-):1118-1131. >>> Toxin, tetanus fragment C; tempol, toxin tetanus fragment C; CSF/CNS; Mice; 2001; 7 days; Stability verified by incubation at 37C for 7 days; brain tissue distribution; post op. care (bupivicaine and betadine in wound); animal info (C57BL/6, male, 25-30 g); dental cement used for cannula adhesion, agent also know as TTC; compounds were also distributed to further brain sites such as the hypothalamus and the thalamus.
P6953 Thaete,L.G., Kushner,D.M., Dewey,E.R., Neerhof,M.G. Endothelin and the regulation of uteroplacental perfusion in nitric oxide synthase inhibition-induced fetal growth restriction. PLACENTA 2005; 26(-2-3-):242-250. >>> L-NAME; A-127722; Saline; ethyl alcohol; NaOH; water; propylene glycol; SC; Rat (pregnant); 2ML1; 1,4,7 days; Functionality of mp verified by residual volume; stability verified by prior experiment (24 days); multiple pumps per animal (2); drugs infused in separate pumps; A-127722 (ETA receptor antagonist) was dissolved in 20% alcohol, 40% PG and 0.04 M of NaOH.
P6894 Tejeda,M, Gaal,D., Csuka,O., Keri,G.Y. Growth Inhibitory Effect of the Somatostatin Structural Derivative (TT-232) on Leukemia Models. Anticancer Research 2005; 25(--):325-330. >>> TT-232; Acetic acid; sodium acetate; water; mannitol; IV; SC; Mice; 2002; 14, 28 days; Dose-response (p. 328, fig 1); comparison of IP/SC injections vs. SC/IV mp; pumps replaced at day 14 for 28 day group; stability verified, 37 degrees Celsius for over 3 weeks; cancer (leukemia); TT-232 is a novel somatostatin analog; "The IV infusion for 28 days resulted in 82% growth inhibition." (p. 328); "The infusion of TT-232 by ALZET osmotic minipump resulted in 70-80% tumor growth inhibition and 20% tumor free survival." (p. 329); "…serial injections represent significant stress to the animals…" "To reduce and eliminate the above mentioned problem [stress] we used an ALZET osmotic minipump…" "Infusion from inserted ALZET minipumps maintains a constant drug level, resulting in a well defined, consistent pattern of drug exposure throughout the period of drug administration." "These studies suggest that TT-232 is a potent inhibitor of leukemia tumor in vitro and in vivo and suggest infusion treatment as a beneficial application in clinical practice." (p. 330); oligopeptide; enzyme inhibitor (tyrosine kinase); animal info (CBA/ca, immunosuppressed, female).
Since 1977, scientist around the world have used ALZET pumps to conduct their research, publishing their results in high-impact journals. The ALZET bibliography now contains over 16,000 publications! We can perform a custom search for references relevant to your research.
What researchers are saying...
“This study showed that pump-controlled delivery of a Nogo-A-specific antibody (7B12) initiated 24 hours after experimental stroke promoted improvement of long-term neurologic outcome in normotensive and SHR rats.” Wiessner et al, J Cereb Blood Flow Metab 2003;23(2):162.